# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwri...
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Prop...
After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an u...